Arovella Therapeutics (ASX:ALA) Total Equity: A$18.92 Mil (As of Dec. 2025)


What is Arovella Therapeutics Total Equity?

Arovella Therapeutics ASX:ALA Total Equity is A$18.92 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Arovella Therapeutics's total equity for the quarter that ended in Dec. 2025 was A$18.92 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Arovella Therapeutics Total Equity Historical Data

* Premium members only.

The historical data trend for Arovella Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arovella Therapeutics Total Equity Chart

Arovella Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.98 7.62 3.78 11.23 20.08

Arovella Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.13 11.23 11.54 20.08 18.92

Arovella Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Arovella Therapeutics's Total Equity for the fiscal year that ended in Jun. 2025 is calculated as

Total Equity=Total Assets(Q: Jun. 2025 )-Total Liabilities(Q: Jun. 2025 )
=21.6-1.524
=20.08

Arovella Therapeutics's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=20.247-1.329
=18.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of A$18.92 Mil mean?
Arovella Therapeutics (ASX:ALA) has a Total Equity of A$18.92 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Arovella Therapeutics and its competitors.
Is Arovella Therapeutics' Total Equity too high?
Arovella Therapeutics' current Total Equity is A$18.92 Mil.
How does Arovella Therapeutics' Total Equity compare to VRTX and REGN?
Arovella Therapeutics' Total Equity of A$18.92 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Arovella Therapeutics and its competitors. Arovella Therapeutics's current Total Equity is A$18.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arovella Therapeutics stock overvalued right now?
Arovella Therapeutics (ASX:ALA) has a current Total Equity of A$18.92 Mil. The current Total Equity is A$18.92 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Arovella Therapeutics (ASX:ALA), the current Total Equity is A$18.92 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Arovella Therapeutics Business Description

Other Exchanges E4NA:Germany
Address 84 Hotham Street, Corporate One, Preston, VIC, AUS, 3072
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.